Skip to main content

Table 3 Subgroup analysis of exacerbations

From: Corticosteroid plus β2-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis

Comparisons

Exacerbations

Severe exacerbations

No. of Studies

ICS/FABA

FABA or ICS

RR (95% CI)

P value

Power

No. of Studies

ICS/FABA

FABA or ICS

RR (95% CI)

P value

Power

ICS/FABA vs. FABA regimen

 All

4 [17, 27, 29, 30]

42/348

68/295

0.56 (0.40, 0.78)

0.001

1.00

3 [17, 27, 29]

25/238

41/239

0.64 (0.44, 0.95)

0.026

0.89

 Adult

2 [17, 27]

6/167

26/165

0.24 (0.10, 0.54)

0.001

0.98

2 [17, 27]

0/167

5/165

0.17 (0.02, 1.35)

0.093

0.47

 Children and adolescent

2 [29, 30]

36/181

42/130

0.76 (0.53, 1.10)

0.147

0.76

1 [29]

25/71

36/74

0.72 (0.49, 1.07)

0.107

0.34

ICS/FABA vs. ICS regimen

 All

4 [17, 26, 29, 30]

111/553

79/537

1.39 (1.08, 1.79)

0.011

1.00

3 [17, 26, 29]

94/443

70/427

1.34 (1.02,1.75)

0.034

0.91

 Adult

1 [17]

6/122

9/106

0.58 (0.21, 1.57)

0.284

0.17

1 [17]

0/122

3/106

0.12 (0.01,2.38)

0.166

0.22

 Children and adolescent

3 [26, 29, 30]

105/431

70/431

1.50 (1.15, 1.96)

0.003

1.00

2 [26, 29]

94/321

67/321

1.40 (1.07,1.84)

0.014

0.81

  1. no. number, CI confidence interval, ICS inhaled corticosteroids, FABA fast-onset-acting β2-agonist, ICS/FABA inhaled corticosteroids/fast-onset-acting β2-agonist
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us